- Home
- SRTS vs JLS Comparison
SRTS vs JLS Comparison
Compare SRTS & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- JLS
- Stock Information
- Founded
- SRTS 2010
- JLS 2009
- Country
- SRTS United States
- JLS United States
- Employees
- SRTS N/A
- JLS N/A
- Industry
- SRTS Medical/Dental Instruments
- JLS Investment Managers
- Sector
- SRTS Health Care
- JLS Finance
- Exchange
- SRTS Nasdaq
- JLS Nasdaq
- Market Cap
- SRTS 106.0M
- JLS 99.0M
- IPO Year
- SRTS 2016
- JLS N/A
- Fundamental
- Price
- SRTS $8.89
- JLS $18.23
- Analyst Decision
- SRTS Strong Buy
- JLS
- Analyst Count
- SRTS 2
- JLS 0
- Target Price
- SRTS $12.50
- JLS N/A
- AVG Volume (30 Days)
- SRTS 262.3K
- JLS 26.6K
- Earning Date
- SRTS 11-14-2024
- JLS 01-01-0001
- Dividend Yield
- SRTS N/A
- JLS 9.33%
- EPS Growth
- SRTS N/A
- JLS N/A
- EPS
- SRTS 0.57
- JLS N/A
- Revenue
- SRTS $41,308,000.00
- JLS N/A
- Revenue This Year
- SRTS $55.14
- JLS N/A
- Revenue Next Year
- SRTS $21.75
- JLS N/A
- P/E Ratio
- SRTS $15.62
- JLS N/A
- Revenue Growth
- SRTS 65.62
- JLS N/A
- 52 Week Low
- SRTS $2.05
- JLS $15.48
- 52 Week High
- SRTS $9.20
- JLS $17.97
- Technical
- Relative Strength Index (RSI)
- SRTS 75.94
- JLS 47.49
- Support Level
- SRTS $6.70
- JLS $17.92
- Resistance Level
- SRTS $9.20
- JLS $18.56
- Average True Range (ATR)
- SRTS 0.56
- JLS 0.19
- MACD
- SRTS 0.21
- JLS -0.00
- Stochastic Oscillator
- SRTS 89.08
- JLS 35.61
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The Fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.